Verastem (VSTM) to Release Quarterly Earnings on Thursday

Key Points

• Verastem is expected to announce its Q2 2025 earnings on August 7th, forecasting a loss of ($0.64) per share and revenue of $6.01 million.
• Recent stock performance shows Verastem trading at $6.23 with a market capitalization of $342.34 million, but it has struggled with earnings, reporting a loss of ($0.96) per share for the last quarter.
• Analyst ratings for Verastem are mixed, with one "sell," eight "buy" ratings, and an average target price of $13.38, following various adjustments from different financial institutions.

Verastem (NASDAQ:VSTM - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.64) per share and revenue of $6.01 million for the quarter.

Verastem (NASDAQ:VSTM - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.24). On average, analysts expect Verastem to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Verastem Trading Down 1.5%

Verastem stock traded down $0.09 during midday trading on Friday, hitting $6.08. The stock had a trading volume of 2,022,690 shares, compared to its average volume of 2,232,027. The stock has a market cap of $334.10 million, a P/E ratio of -1.90 and a beta of 0.83. Verastem has a 12 month low of $2.10 and a 12 month high of $9.10. The business has a fifty day moving average price of $5.56 and a 200 day moving average price of $6.02.

Analyst Upgrades and Downgrades

VSTM has been the subject of several research analyst reports. Jefferies Financial Group initiated coverage on Verastem in a report on Thursday, April 10th. They issued a "buy" rating and a $15.00 price objective for the company. Mizuho decreased their target price on Verastem from $9.00 to $8.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Royal Bank Of Canada upgraded Verastem from an "outperform" rating to a "moderate buy" rating and decreased their target price for the company from $16.00 to $12.00 in a research note on Wednesday, June 25th. Wall Street Zen downgraded Verastem from a "hold" rating to a "sell" rating in a research note on Friday, April 18th. Finally, HC Wainwright lifted their target price on Verastem from $10.00 to $14.00 and gave the company a "buy" rating in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $13.38.

Insider Buying and Selling

In other news, CFO Daniel Calkins sold 11,143 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.13, for a total transaction of $90,592.59. Following the completion of the transaction, the chief financial officer directly owned 114,055 shares in the company, valued at approximately $927,267.15. The trade was a 8.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Dan Paterson sold 58,677 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.13, for a total value of $477,044.01. Following the transaction, the chief executive officer owned 461,982 shares of the company's stock, valued at approximately $3,755,913.66. This represents a 11.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 93,796 shares of company stock valued at $693,033. 2.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Verastem

A hedge fund recently raised its stake in Verastem stock. AQR Capital Management LLC lifted its holdings in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) by 78.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 62,603 shares of the biopharmaceutical company's stock after buying an additional 27,477 shares during the period. AQR Capital Management LLC owned approximately 0.12% of Verastem worth $377,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 88.37% of the company's stock.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.